Edition:
India

Horizon Therapeutics PLC (HZNP.OQ)

HZNP.OQ on NASDAQ Stock Exchange Global Select Market

24.63USD
18 Jul 2019
Change (% chg)

-- (--)
Prev Close
$24.63
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
635,532
52-wk High
$29.44
52-wk Low
$16.57

Latest Key Developments (Source: Significant Developments)

Horizon Therapeutics Announces Proposed Private Offering Of Senior Notes
Wednesday, 10 Jul 2019 

July 10 (Reuters) - Horizon Therapeutics PLC ::HORIZON THERAPEUTICS PLC ANNOUNCES PROPOSED PRIVATE OFFERING OF SENIOR NOTES.HORIZON THERAPEUTICS PLC -UNIT INTENDS TO OFFER $500 MILLION AGGREGATE PRINCIPAL AMOUNT OF SENIOR NOTES DUE 2027.HORIZON THERAPEUTICS PLC - EXPECTS TO USE NET PROCEEDS FROM OFFERING TO REDEEM $525 MILLION OF ITS OUTSTANDING DEBT.  Full Article

Horizon Therapeutics Initiates Trial Evaluating Krystexxa In Combination With Methotrexate
Thursday, 20 Jun 2019 

June 20 (Reuters) - Horizon Therapeutics PLC ::HORIZON THERAPEUTICS PLC INITIATES MIRROR RANDOMIZED CONTROLLED TRIAL EVALUATING KRYSTEXXA® (PEGLOTICASE INJECTION) IN COMBINATION WITH METHOTREXATE TO INCREASE RESPONSE RATES AND DURATION OF THERAPY.  Full Article

Horizon Therapeutics Says Unit Borrowed $518 Million Of Loans Pursuant To An Amendment To Credit Agreement, Dated As Of May 7, 2015
Thursday, 23 May 2019 

May 22 (Reuters) - Horizon Therapeutics PLC ::HORIZON THERAPEUTICS PLC - HORIZON PHARMA USA BORROWED $518 MILLION OF LOANS PURSUANT TO AN AMENDMENT TO CREDIT AGREEMENT, DATED AS OF MAY 7, 2015.HORIZON THERAPEUTICS PLC - REFINANCING LOANS WERE INCURRED AS A SEPARATE NEW CLASS OF TERM LOANS UNDER CREDIT AGREEMENT.HORIZON THERAPEUTICS PLC - REFINANCING LOANS EXTEND FINAL MATURITY DATE TO MAY 22, 2026.HORIZON THERAPEUTICS PLC - HORIZON PHARMA USA USED PROCEEDS OF REFINANCING LOANS TO REPAY REFINANCED LOANS WHICH TOTALED $518 MILLION.  Full Article

Horizon Pharma Plc Reports First-Quarter 2019 Net Sales Of $280.4 Million, Up 25 Percent
Wednesday, 8 May 2019 

May 8 (Reuters) - Horizon Pharma PLC ::HORIZON THERAPEUTICS PLC REPORTS STRONG FIRST-QUARTER 2019 RESULTS; INCREASES FULL‐YEAR 2019 NET SALES AND ADJUSTED EBITDA GUIDANCE.FIRST-QUARTER 2019 NET SALES OF $280.4 MILLION INCREASED 25 PERCENT.INCREASING FULL-YEAR 2019 NET SALES GUIDANCE RANGE TO $1.26 BILLION TO $1.28 BILLION.CONTINUE TO EXPECT MID-2019 U.S. BIOLOGICS LICENSE APPLICATION (BLA) SUBMISSION.QTRLY LOSS PER SHARE $0.19.QTRLY ADJUSTED EARNINGS PER SHARE $0.30.INCREASING FULL-YEAR 2019 ADJUSTED EBITDA GUIDANCE RANGE TO $450 MILLION TO $465 MILLION.Q1 EARNINGS PER SHARE VIEW $0.12, REVENUE VIEW $238.3 MILLION -- REFINITIV IBES DATA.FY2019 REVENUE VIEW $1.24 BILLION -- REFINITIV IBES DATA.  Full Article

Horizon Pharma Sells Rights To Ravicti & Ammonaps Outside N.America and Japan
Friday, 4 Jan 2019 

Jan 4 (Reuters) - Horizon Pharma PLC ::HORIZON PHARMA PLC - ON DEC 28 SOLD RIGHTS TO RAVICTI & AMMONAPS OUTSIDE OF N. AMERICA, JAPAN TO MEDICAL NEED EUROPE AB, FOR $35 MILLION.HORIZON PHARMA - TO RETAIN RIGHTS TO RAVICTI & AMMONAPS/BUPHENYL IN NORTH AMERICA & JAPAN.HORIZON PHARMA PLC - WILL RETAIN RIGHTS TO RAVICTI AND AMMONAPS/BUPHENYL IN NORTH AMERICA AND JAPAN.HORIZON PHARMA PLC - WILL NO LONGER RECOGNIZE REVENUE FROM RAVICTI AND AMMONAPS SALES OUTSIDE OF NORTH AMERICA AND JAPAN.  Full Article

Horizon Pharma PLC And Hemoshear Therapeutics Enter Into Exclusive Drug Discovery Collaboration
Thursday, 3 Jan 2019 

Jan 3 (Reuters) - Horizon Pharma PLC ::HORIZON PHARMA PLC AND HEMOSHEAR THERAPEUTICS ENTER INTO EXCLUSIVE DRUG DISCOVERY COLLABORATION IN GOUT.HORIZON PHARMA PLC - FURTHER FINANCIAL TERMS WERE NOT DISCLOSED..HORIZON PHARMA PLC - UNDER TERMS OF AGREEMENT, HEMOSHEAR WILL RECEIVE UPFRONT PAYMENTS AND RESEARCH AND DEVELOPMENT FUNDING.HORIZON PHARMA PLC - HORIZON WILL RECEIVE EXCLUSIVE ACCESS TO HEMOSHEAR'S PROPRIETARY DISEASE MODELING PLATFORM TO DISCOVER NEW THERAPEUTICS FOR GOUT.  Full Article

Horizon Pharma Announces FDA Approval To Expand Age Range For Ravicti
Thursday, 27 Dec 2018 

Dec 27 (Reuters) - Horizon Pharma PLC ::HORIZON PHARMA PLC ANNOUNCES FDA APPROVAL TO EXPAND THE AGE RANGE FOR RAVICTI® (GLYCEROL PHENYLBUTYRATE) ORAL LIQUID TO INCLUDE NEWBORNS.  Full Article

Horizon Pharma - Entered Into Settlement Agreement With Par Pharmaceutical
Thursday, 20 Sep 2018 

Sept 20 (Reuters) - Horizon Pharma PLC ::HORIZON PHARMA - ON SEPTEMBER 17, CO'S UNIT ENTERED INTO A SETTLEMENT AGREEMENT WITH PAR PHARMACEUTICAL RELATING TO RAVICTI ORAL LIQUID, 1.1 GM/ML.HORIZON PHARMA PLC - SETTLEMENT AGREEMENT PERTAINS TO ON-GOING PATENT INFRINGEMENT LITIGATION AGAINST PAR IN DSITRICT COURT.HORIZON PHARMA - PARTIES HAVE AGREED TO FILE STIPULATIONS OF DISMISSAL WITH COURTS REGARDING LITIGATION AND JOINT REQUEST FOR TERMINATION IN THE IPRS.HORIZON PHARMA - UNIT GRANTED PAR NON-EXCLUSIVE, ROYALTY-FREE LICENSE TO MANUFACTURE, COMMERCIALIZE PAR'S GENERIC VERSION OF RAVICTI IN U.S..HORIZON - SETTLEMENT AGREEMENT PROVIDES FULL SETTLEMENT, RELEASE BY PARTIES OF CLAIMS THAT RELATE TO PAR’S GENERIC VERSION OF RAVICTI OR LITIGATION OR IPRS.HORIZON PHARMA - AGREEMENT ALSO PERTAINS TO PETITIONS FOR INTER PARTES REVIEW WITH PATENT TRIAL & APPEAL BOARD WITH CERTAIN U.S. PATENTS FOR RAVICTI.HORIZON - UNDER SETTLEMENT AGREEMENT WITH PAR, LICENSE EFFECTIVE DATE IS JULY 1, 2025 - SEC FILING.HORIZON PHARMA - LICENSE GRANTED TO PAR FOR MANUFACTURE OF ITS GENERIC VERSION OF RAVICTI EFFECTIVE AFTER LICENSE EFFECTIVE DATE OF JULY 1, 2025.HORIZON -UNIT AGREED NOT TO SUE,ASSERT CLAIM AGAINST PAR FOR INFRINGEMENT OF PATENT & PATENT APPLICATION OWNED OR CONTROLLED BY UNIT DURING AGREEMENT.HORIZON - PAR AGREED NOT TO CHALLENGE THE VALIDITY OR ENFORCEABILITY OF THE LICENSED PATENTS.  Full Article

Horizon Pharma PLC Announces Q4 Non-Gaap Earnings Per Share $0.29
Wednesday, 28 Feb 2018 

Feb 28 (Reuters) - Horizon Pharma Plc ::ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2017 RESULTS.Q4 NON-GAAP EARNINGS PER SHARE $0.29.SEES FY 2018 SALES $1.15 BILLION TO $1.18 BILLION.Q4 SALES $274.2 MILLION.Q4 GAAP LOSS PER SHARE $0.28.‍FULL-YEAR 2018 ADJUSTED EBITDA GUIDANCE OF $370 MILLION TO $395 MILLION​.Q4 EARNINGS PER SHARE VIEW $0.22, REVENUE VIEW $264.5 MILLION -- THOMSON REUTERS I/B/E/S.FY2018 REVENUE VIEW $1.14 BILLION -- THOMSON REUTERS I/B/E/S.HORIZON PHARMA SAYS Q4 NET SALES DRIVEN BY CONTINUED STRONG GROWTH FROM CO'S ORPHAN & RHEUMATOLOGY BUSINESS UNITS​.  Full Article

Horizon Pharma Sees Krystexxa FY 2018 Sales Up More Than 50 Percent
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Horizon Pharma Plc ::HORIZON PHARMA SEES KRYSTEXXA FY 2018 SALES UP MORE THAN 50 PERCENT.HORIZON PHARMA PLC - INCREASING ITS ESTIMATED PEAK ANNUAL NET SALES EXPECTATIONS FOR EACH MEDICINE TO MORE THAN $750 MILLION.HORIZON PHARMA PLC INCREASES PEAK NET SALES GUIDANCE FOR KEY GROWTH DRIVERS AND ANNOUNCES RHEUMATOLOGY AND ORPHAN PIPELINE DEVELOPMENTS.  Full Article

Recordati to seek Canadian approval for kidney disease drug

TORONTO Italy's Recordati said on Tuesday it plans to seek Canadian approval for its drug Cystagon, which treats a rare kidney disease, in a potential blow to Horizon Pharma,, which makes the only drug approved for treatment in Canada.